Zogenix rises on anticipated FDA Zohydro action
This article was originally published in Scrip
Executive Summary
Shares of Zogenix rose as high as 29.2% on 2 October after the company said the FDA could soon make a decision on whether it will permit the firm to market its extended-release (ER) single-entity hydrocodone analgesic Zohydro ER in the US – declaring an action letter is expected after a short delay.